Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children

Dev Med Child Neurol. 2015 Jan;57(1):95-9. doi: 10.1111/dmcn.12545. Epub 2014 Jul 16.

Abstract

Anti-NDMA receptor (NMDAR) encephalitis is an auto-immune condition. There is no uniformly agreed treatment strategy for the disorder in children. We report the use of intrathecal treatment with methotrexate and methylprednisolone in three children (one male, two females, age 10y, 11y, and 14y) with anti-NMDAR encephalitis, who did not respond to steroids, plasmapheresis, or rituximab. There was significant clinical improvement and stabilization of the anti-NMDAR antibody titers in cerebrospinal fluid (CSF) and blood in two patients. In the third patient, although anti-NMDAR antibody titers in CSF decreased, clinical recovery was less satisfactory. Intrathecal treatment with methotrexate and methylprednisolone seems to be a promising alternative treatment for some paediatric cases of resistant anti-NMDAR encephalitis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / blood
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / cerebrospinal fluid
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / drug therapy*
  • Antibodies / blood
  • Antibodies / cerebrospinal fluid
  • Antibodies / drug effects*
  • Child
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / pharmacology*
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / pharmacology*
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / pharmacology*
  • Subarachnoid Space / drug effects
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies
  • Immunosuppressive Agents
  • Methylprednisolone
  • Methotrexate